Table 3.
The Bi-Variable and Multivariable Cox-Regression Analysis of the Predictors of OI Among Adult HIV Patients on ART at Dessie Comprehensive Specialized Hospital, Northeast Ethiopia from January 2015 to December 2020 (n = 354)
| Variable | Survival Status | CHR (95% CI) | AHR (95% CI) | |
|---|---|---|---|---|
| Event | Censored | |||
| Residency | ||||
| Urban | 107 | 214 | 1.7(0.79–3.66) | 1.3(0.60–2.92) |
| Rural | 7 | 26 | 1 | 1 |
| Disclosure status | ||||
| Not disclosed | 21 | 26 | 1 | 1 |
| Disclosed | 83 | 184 | 0.63(0.39–1.03) | 0.69(0.42–1.14) |
| Not recorded | 10 | 30 | 0.5(0.235–1.06) | 0.72(0.33–1.58) |
| Functional status | ||||
| Working | 43 | 135 | 1 | 1 |
| Ambulatory | 30 | 64 | 1.46(0.91–2.33) | 1.25(0.74–2.09) |
| Bedridden | 41 | 41 | 2.36(1.54–3.62) | 1.66(1.04–2.65)* |
| Adherence | ||||
| Poor | 30 | 25 | 2.05(1.35–3.11) | 1.7(1.1–2.63)* |
| Good | 84 | 215 | 1 | 1 |
| WHO clinical stage | ||||
| Stage I | 21 | 75 | 1 | 1 |
| Stage II | 29 | 91 | 1.12(0.64–1.98) | 1.1(0.62–2.63) |
| Stage III | 28 | 46 | 1.9(1.07–3.34) | 1.66(0.92–2.97) |
| Stage IV | 36 | 28 | 3.12(1.82–5.35) | 2.1(1.16–3.8)* |
| CD4 cell count | ||||
| ≤200 | 56 | 59 | 2.6(1.62–4.16) | 1.92(1.14–3.22)* |
| 201–350 | 33 | 88 | 1.22(0.73–2.06) | 1.08(0.63–1.84) |
| ≥351 | 25 | 93 | 1 | 1 |
| Hemoglobin | 114 | 240 | 0.94(0.86–1.03) | 0.93(0.84–1.02) |
| BMI | ||||
| <18.5 | 44 | 71 | 1.44(0.98–2.1) | 1.4(0.92–2.13) |
| ≥18.5 | 70 | 169 | 1 | 1 |
| CPT | ||||
| Yes | 98 | 184 | 1 | 1 |
| No | 16 | 56 | 0.6(0.35–1.01) | 0.64(0.37–1.10) |
Notes: *Indicates significance which have P-value <0.05 in multivariable cox proportional hazard model.
Abbreviations: BMI, body mass index; CPT, cotrimoxazole preventive therapy.